Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma

businesswire

Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma – NEWSnet – News… as it used to be

More Press Releases

June 11, 2026

SERVICE CORPORATION INTERNATIONAL INCREASES SHARE REPURCHASE AUTHORIZATION

June 11, 2026

Bank of America Declares Preferred Stock Dividends Payable in July and August 2026

June 11, 2026

ARES DYNAMIC CREDIT ALLOCATION FUND DECLARES A MONTHLY DISTRIBUTION OF $0.1125 PER SHARE

June 11, 2026

Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma

SERVICE CORPORATION INTERNATIONAL INCREASES SHARE REPURCHASE AUTHORIZATION

Bank of America Declares Preferred Stock Dividends Payable in July and August 2026

ARES DYNAMIC CREDIT ALLOCATION FUND DECLARES A MONTHLY DISTRIBUTION OF $0.1125 PER SHARE

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit